S
Sanjay Popat
Researcher at Institute of Cancer Research
Publications - 406
Citations - 18452
Sanjay Popat is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 45, co-authored 315 publications receiving 13802 citations. Previous affiliations of Sanjay Popat include Imperial College London & The Royal Marsden NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
Silvia Novello,Fabrice Barlesi,Raffaele Califano,Raffaele Califano,Tanja Cufer,Simon Ekman,M. Giaj Levra,Keith M. Kerr,Sanjay Popat,Martin Reck,Suresh Senan,G Simo,Johan Vansteenkiste,Sanne Peters +13 more
TL;DR: The ESMO Guidelines Committee concluded that current state-of-the-art oncology practices in France, Belgium, and the Netherlands are suitable for frontline use and recommend further research into these practices.
Journal ArticleDOI
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
TL;DR: CRCs with MSI have a significantly better prognosis compared to those with intact mismatch repair, and additional studies are needed to further define the benefit of adjuvant chemotherapy in locally advanced tumors with MSI.
Journal ArticleDOI
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang,Yi-Long Wu,Martin Schuler,Martin Sebastian,Sanjay Popat,Nobuyuki Yamamoto,Caicun Zhou,Cheng Ping Hu,Kenneth J. O'Byrne,Jifeng Feng,Shun Lu,Yunchao Huang,Sarayut Lucien Geater,Kye Young Lee,Chun-Ming Tsai,Vera Gorbunova,Vera Hirsh,Jaafar Bennouna,S. M. Orlov,Tony Mok,Michael Boyer,Wu Chou Su,Ki Hyeong Lee,Terufumi Kato,Dan Massey,Mehdi Shahidi,Victoria Zazulina,Lecia V. Sequist +27 more
TL;DR: In this article, the effect of Afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials was evaluated.
Journal ArticleDOI
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Journal ArticleDOI
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazieres,Alexander Drilon,Amélie Lusque,Laurent Mhanna,Alexis B. Cortot,Laura Mezquita,A. Thai,C. Mascaux,Sébastien Couraud,Remi Veillon,M. van den Heuvel,Joel W. Neal,Nir Peled,Martin Früh,Terry L. Ng,Valérie Gounant,Sanjay Popat,Joachim Diebold,Joshua K. Sabari,Viola W. Zhu,Sacha I. Rothschild,Paolo Bironzo,Alex Martinez-Marti,Alessandra Curioni-Fontecedro,Rafael Rosell,Mickaël Lattuca-Truc,Marcel Wiesweg,Benjamin Besse,Benjamin Solomon,Fabrice Barlesi,R.D. Schouten,Heather A. Wakelee,D.R. Camidge,Gérard Zalcman,Silvia Novello,S-H.I. Ou,Julie Milia,Oliver Gautschi +37 more
TL;DR: In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.